Vicore has dosed the first patient in a study assessing the effect of its angiotensin II type 2 receptor agonist (ATRAG) C21 on endothelial dysfunction in type-2-diabetes-mellitus patients.
A simple, non-invasive FDA-approved technology, EndoPAT is used for identifying endothelial dysfunction in the proof-of-concept, double-blind, randomised, placebo-controlled, cross-over study.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It can also be used to investigate therapeutic efficacy in diseases driven by endothelial dysfunction and determine the active dose-range for new ATRAGs.
Vicore Pharma clinical operations vice-president Elin Rosendahl said: “Measuring endothelial dysfunction with the EndoPAT technology in drug trials is a cost-effective and robust method for early documentation of proof-of-concept in pulmonary, renal and vascular diseases.
“This has the potential to substantially shorten the timelines and decrease the risk in clinical development programmes.”
Endothelial dysfunction is a key driver of organ damage and is characterised by a proinflammatory and prothrombotic state with impaired microvascular blood flow.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataLund University experimental cardiology professor and trial principal investigator Jan Nilsson said: “Patients with diabetes mellitus have an increased risk of cardiovascular events and endothelial dysfunction is an important factor for this development.
“Treating endothelial dysfunction could be a major breakthrough in cardiovascular disease.”
Results from the trial are expected in the fourth quarter of this year.
